Last Modified: February 10, 2003
Conference Dates: October 16-18, 2003
Conference Location: New York, NY
Sponsoring Group: Imedex, Inc.
Conference Web Page URL: www.imedex.com/announcements/silver03.htm
Session 1: Myelodysplasia
Session 2: Myelofibrosis
Session 3: New diagnostic markers in polycythemia vera
Session 4: Essential thrombocytosis and related disorders
Session 5: Chronic myeloid leukemia
Conference Objectives: After successfully completing this program, participants should be able to: Discuss the role of angiogenetic and vascular growth factors in myelodysplasia and the various myeloproliferative disorders, Provide an overview of the current medical and alternative therapies for the myelodysplastic disorders, Recommend the most appropriate management strategies for myelofibrosis and chronic myeloid leukemia, Discuss the merits of new genetic markers for the diagnosis of polycythemia vera
Who Should Attend: This educational program is intended for physicians and other health care providers who are involved in and/or interested in myelodysplasia or myeloproliferative disorders. No specific knowledge or skills other than a basic training or familiarity with the practice of hematology is required for successful participation in this program.
Conference Fees: Physicians, Discounted $249 if received at Imedex on or before Thursday, July 31, 2003, Regular $399 if received at Imedex on or before Thursday, October 2, 2003, On-Site $499 if received at Imedex after Thursday, October 2, 2003. Nurses, Fellows or Residents, Discounted $199 if received at Imedex on or before Thursday, July 31, 2003, Regular $299, if received at Imedex on or before Thursday, October 2, 2003, On-Site $399 if received at Imedex after Thursday, October 2, 2003.
Continuing Education: Yes
Miscellany: Call for Abstracts: Participants interested in presenting data should submit abstracts online at www.imedex.com by August 15, 2003. CME: 15.25 hours, category 1. Conference chairman: Richard T. Silver, MD,, Cornell University Medical College
Oct 24, 2014 - Overall survival for multiple myeloma patients has increased substantially in recent decades for patients aged 65 years or younger, while prognosis for survival in patients with myelodysplastic syndromes can be determined by methylation in key genes, according to a pair of studies published online Dec. 28 in the Journal of Clinical Oncology.